Shares of Arcturus Therapeutics ARCT fell in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were down 220.90% over the past year to ($2.15), which missed the estimate of ($1.25).
Revenue of $2,127,000 decreased by 19.61% from the same period last year, which missed the estimate of $2,540,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 10, 2021
Time: 04:30 PM
ET Webcast URL: http://public.viavid.com/player/index.php?id=144682
Technicals
Company's 52-week high was at $129.71
52-week low: $28.92
Price action over last quarter: down 46.42%
Company Description
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-2020.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
